ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2276

Use of Methotrexate and TNF-α Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: A Survey of Rheumatologists
Abstract Number: 2277

Switching to a Targeted Drug with a Different Mode of Action After Discontinuation of the First TNF Inhibitor Is Associated with Better Drug Survival Compared to a Second TNF Inhibitor in Rheumatoid Arthritis: A Propensity Score-matched Analysis from the Czech ATTRA Registry
Abstract Number: 2278

Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
Abstract Number: 2279

Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care
Abstract Number: 2280

Development of a Blood-based Cell-free DNA Classifier Assay to Predict Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients (PRIMA-102)
Abstract Number: 2281

Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
Abstract Number: 2282

Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response
Abstract Number: 2283

Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry
Abstract Number: 2284

Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice
Abstract Number: 2285

Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol
Abstract Number: 2286

Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Abstract Number: 2287

Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study
Abstract Number: 2288

Interferon Gamma Signaling Is Associated with Development of Extraglandular Manifestations in Sjögren’s Disease
Abstract Number: 2289

Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study
Abstract Number: 2290

Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].